IP Library Granted Patent US 11,896,609
Granted Patent B2
US 11,896,609 · App. 17/893,937 · Granted Feb 13, 2024

Pharmaceutical composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone

Inventors: Kyung-Hwa Yoo (Seoul, KR); Jun Ho Song (Seodaemun-gu, KR); Yong-Beom Park (Seocho-gu, KR); Sun-Mi Lee (Gangseo-gu, KR); Chin Hee Mun (Gyeonggi-do, KR); Taejun Yoon (Seodaemun-gu, KR)
Assignee: Industry-Academic Cooperation Foundation
A61K33/24A61K9/0029A61K9/0056A61K9/284A61K9/5115A61K33/00A61K33/04A61P1/04A61P29/00A61P37/00A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,896,609
App. No.
17/893,937
Granted
Feb 13, 2024
Kind
B2
Abstract

The present invention relates to a composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone, and the nanosheets have excellent anti-inflammatory and thus are excellent in treating inflammatory bowel disease and psoriasis.

Claims (7)

1. A method of treating inflammatory diseases, comprising administering a pharmaceutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprise a single layer of germanium telluride nanosheets coated with polyvinylpyrrolidone as an active ingredient.

2. The method of claim 1 , wherein the inflammatory diseases are is one or more diseases selected from the group consisting of inflammatory bowel disease, psoriasis, atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus.

3. The method of claim 1 , wherein the inflammatory bowel diseases are Crohn's disease or ulcerative colitis.

4. The method of claim 1 , wherein the nanosheets suppress the expression of pro-inflammatory factors and increases the expression of anti-inflammatory factors.

5. The method of claim 4 , wherein the pro-inflammatory factors are is selected from the group consisting inducible nitric oxide synthase (iNOS), tumor necrosis factor-α(TNF-α) and interleukin-1β.

6. The method of claim 4 , wherein the anti-inflammatory factors are Arginasel (Arg 1) or cluster of differentiation 206 (CD206).

7. The method of claim 1 , wherein the pharmaceutical composition is a formulation for oral or parenteral administration.

Assignments (2)
CHANGE OF NAME Recorded Sep 24, 2024
From: INDUSTRY-ACADEMIC COOPERATION FOUNDATION
To: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Reel/Frame 068682/0779 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: YOO, KYUNG-HWA; SONG, JUN HO; PARK, YONG-BEOM; LEE, SUN-MI; MUN, CHIN HEE; YOON, TAEJUN
To: INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 061312/0127 →
Priority Claims (1)
KR 10-2021-0111826 · Aug 24, 2021 · national
Continuity (1)
Related Publication 20230080524A1 · Mar 16, 2023